Nuclera, a biotech firm from Cambridge, UK, secured $75M to advance their protein expression technology.

The funding, spearheaded by Elevage Medical Technologies with major contributions from Patient Square Capital and others, will aid in the commercialization of the eProtein Discovery system in the US and Europe.

Nuclera aims to revolutionize protein purification, offering rapid solutions for labs using AI in protein design with their innovative technology.

Already adopted by leading institutions like University College London and University of Cambridge, the system slashes processing times drastically, proving a game-changer for research and biotech applications.